Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYCC
CUSIPN/A
Phone908-517-7330
Debt
Debt-to-Equity RatioN/A
Current Ratio5.82
Quick Ratio5.82
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$840,000.00
Price / Sales21.29
Cash FlowN/A
Price / CashN/A
Book Value$1.83 per share
Price / Book0.81
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-7,470,000.00
Net MarginsN/A
Return on Equity-37.72%
Return on Assets-30.76%
Miscellaneous
Employees12
Outstanding Shares12,000,000
Market Cap$17.88
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions
What is Cyclacel Pharmaceuticals' stock symbol?
Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."
When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?
Cyclacel Pharmaceuticals's stock reverse split on Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.
How were Cyclacel Pharmaceuticals' earnings last quarter?
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) announced its earnings results on Monday, May, 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.01. View Cyclacel Pharmaceuticals' Earnings History.
What is the consensus analysts' recommendation for Cyclacel Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Cyclacel Pharmaceuticals' key competitors?
Some companies that are related to Cyclacel Pharmaceuticals include Merrimack Pharmaceuticals (MACK), IMMUTEP LTD/S (IMMP), KemPharm (KMPH), OncoSec Medical (ONCS), Humanigen (HGEN), OASMIA PHARMACE/ADR (OASM), Helix Biopharma (HBPCF), Eyenovia (EYEN), Novelion Therapeutics (NVLN), Vascular Biogenics (VBLT), Aileron Therapeutics (ALRN), Evofem Biosciences (EVFM), Novus Therapeutics (NVUS), Zosano Pharma (ZSAN) and Celsion (CLSN).
Who are Cyclacel Pharmaceuticals' key executives?
Cyclacel Pharmaceuticals' management team includes the folowing people:
- Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 59)
- Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 57)
- Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 58)
- Prof. David Glover Ph.D., FRS FRSE, Chief Scientist (Age 70)
- Ms. Gill Christie, Director of HR (Age 61)
Has Cyclacel Pharmaceuticals been receiving favorable news coverage?
Media stories about CYCC stock have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a news impact score of 0.14 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 45.38 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Cyclacel Pharmaceuticals?
Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cyclacel Pharmaceuticals' stock price today?
One share of CYCC stock can currently be purchased for approximately $1.49.
How big of a company is Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals has a market capitalization of $17.88 million and generates $840,000.00 in revenue each year. Cyclacel Pharmaceuticals employs 12 workers across the globe.
How can I contact Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]
MarketBeat Community Rating for Cyclacel Pharmaceuticals (NASDAQ CYCC)
MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CYCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
